Affymetrix and Invitrogen Enter Into Licensing Agreement

SANTA CLARA, Calif. & CARLSBAD, Calif.–Affymetrix Inc. (Nasdaq:AFFX) and Invitrogen Corporation (Nasdaq:IVGN) announced today that Invitrogen has obtained a non-exclusive, worldwide license to a number of Affymetrix patents that will allow Invitrogen to manufacture and sell spotted nucleic acid microarrays in the research field. Financial details of the license were not disclosed.

< | >